A prospective, cohort study assessing high success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naive and experienced chronic hepatitis C genotype 4
Latest Information Update: 22 Feb 2022
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
Most Recent Events
- 22 Feb 2022 New trial record
- 01 Feb 2022 Results published in the Journal of Medical Virology